Market Research Logo

Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027

Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027

Future Market Insights presents a detailed forecast of the global biopharmaceutical contract manufacturing market in a new report titled “Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027” and provides vital insights into the various factors influencing the market currently and over the next 10 years. The report dives deep into the various aspects of the global biopharmaceutical contract manufacturing market and analyses the various market segments and their performance over the forecast period 2017 – 2027. A historical analysis for the period 2012 – 2026 serves as a point of reference in estimating the market forecast for the projected 10 year period starting 2017.

A cohesive report structure that facilitates ease of navigation

The report begins with a succinct executive summary that captures the market overview, market analysis, and our recommendations to key market players. The market introduction describes the global biopharmaceutical contract manufacturing market and highlights the market segmentation. In another section, we present the market viewpoint analysis where we describe the macroeconomic factors impacting revenue growth, opportunity analysis, and the regulatory scenario in the global biopharmaceutical contract manufacturing market.

The subsequent sections provide the regional biopharmaceutical contract manufacturing market forecasts for each of the assessed regions. Here we outline the regional market dynamics (drivers, restraints, trends), historical and projected market forecasts for the various market segments and countries, market attractiveness analysis, key representative market participants, and a market presence intensity map. At the end of these sections is a small chapter on the relevance and impact of the various forecast factors on the global biopharmaceutical contract manufacturing market followed by Future Market Insights forecast assumptions.

A very important section of the report focusses on the competition landscape of the global biopharmaceutical contract manufacturing market. This section is intended to provide a dashboard view of the different companies operating in the global biopharmaceutical contract manufacturing market. We provide useful information such as company overview, key financials, business and marketing strategies, a comprehensive SWOT analysis, and recent market developments. We have also profiled the top companies in the global biopharmaceutical contract manufacturing market to enable our readers to acquire a bird’s eye view of the vendor ecosystem of the global biopharmaceutical contract manufacturing market.

The last section provides the numbers pertaining to the global biopharmaceutical contract manufacturing market revenue along with a global market attractiveness analysis for the various segments across the different regional markets. We also present figures pertaining to the market size, Y-o-Y growth, and absolute $ opportunity; as well as the global biopharmaceutical contract manufacturing market value chain.

Global Biopharmaceutical Contract Manufacturing Market: Segmentation

By Platform

By Application

By Product Type

By Therapeutic Area

By Region

Mammalian

Microbial

Clinical

Commercial

Growth Factors

Interferons

Monoclonal Antibodies

Recombinant Hormones

Vaccines

Insulin

Others

Autoimmune Diseases

Oncology

Metabolic Diseases

Ophthalmology

Cardiovascular Diseases

Infectious Diseases

Neurology

Respiratory Disorders

Others

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific excluding Japan

Japan

Middle East & Africa

A multi-pronged approach to the research to ensure near 100% data accuracy

Future Market Insights deploys a systematic research methodology that is at par with the best in the industry to derive the market estimations for the global biopharmaceutical contract manufacturing market over the forecast period. We begin with market profiling (systematic secondary research that helps us analyse the required data points to arrive at the overall market numbers), developing a list of respondents across the global biopharmaceutical contract manufacturing market value chain and a detailed discussion guide for primary research, data collection (exhaustive primary interviews using distinguished essential resources), data validation using the triangulation method (wherein secondary, primary and our in-depth market analysis contribute to the final data), and finally a comprehensive data analysis and scrutiny using advanced tools to obtain pertinent insights into the global biopharmaceutical contract manufacturing market.


1. Executive Summary
1.1. Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Biopharmaceutical Contract Manufacturing Market View Point Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Scenario
4. North America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
4.5.1. Mammalian-based
4.5.2. Microbial-based
4.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
4.6.1. Mammalian-based
4.6.2. Microbial-based
4.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
4.7.1. Monoclonal Antibodies
4.7.2. Recombinant Proteins
4.7.3. Vaccines
4.7.4. Insulin
4.7.5. Interferons
4.7.6. Growth Factors
4.7.7. Others
4.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
4.8.1. Monoclonal Antibodies
4.8.2. Recombinant Proteins
4.8.3. Vaccines
4.8.4. Insulin
4.8.5. Interferons
4.8.6. Growth Factors
4.8.7. Others
4.9. Historical Market Size (US$ Mn) By Application, 2012-2016
4.9.1. Clinical
4.9.2. Commercial
4.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
4.10.1. Clinical
4.10.2. Commercial
4.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
4.11.1. Autoimmune Disease
4.11.2. Oncology
4.11.3. Metabolic Disease
4.11.4. Opthalmology
4.11.5. Cardiovascular Disease
4.11.6. Infectious Disease
4.11.7. Neurology
4.11.8. Respiratory Disorder
4.11.9. Others
4.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
4.12.1. Autoimmune Disease
4.12.2. Oncology
4.12.3. Metabolic Disease
4.12.4. Opthalmology
4.12.5. Cardiovascular Disease
4.12.6. Infectious Disease
4.12.7. Neurology
4.12.8. Respiratory Disorder
4.12.9. Others
4.13. Market Attractiveness Analysis
4.13.1. By Country
4.13.2. By Platform
4.13.3. By Product Type
4.13.4. By Application
4.13.5. By Therapeutic Area
4.14. Key Representative Market Participants
4.15. Market Presence (Intensity Map)
5. Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
5.5.1. Mammalian-based
5.5.2. Microbial-based
5.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
5.6.1. Mammalian-based
5.6.2. Microbial-based
5.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
5.7.1. Monoclonal Antibodies
5.7.2. Recombinant Proteins
5.7.3. Vaccines
5.7.4. Insulin
5.7.5. Interferons
5.7.6. Growth Factors
5.7.7. Others
5.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
5.8.1. Monoclonal Antibodies
5.8.2. Recombinant Proteins
5.8.3. Vaccines
5.8.4. Insulin
5.8.5. Interferons
5.8.6. Growth Factors
5.8.7. Others
5.9. Historical Market Size (US$ Mn) By Application, 2012-2016
5.9.1. Clinical
5.9.2. Commercial
5.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
5.10.1. Clinical
5.10.2. Commercial
5.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
5.11.1. Autoimmune Disease
5.11.2. Oncology
5.11.3. Metabolic Disease
5.11.4. Opthalmology
5.11.5. Cardiovascular Disease
5.11.6. Infectious Disease
5.11.7. Neurology
5.11.8. Respiratory Disorder
5.11.9. Others
5.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
5.12.1. Autoimmune Disease
5.12.2. Oncology
5.12.3. Metabolic Disease
5.12.4. Opthalmology
5.12.5. Cardiovascular Disease
5.12.6. Infectious Disease
5.12.7. Neurology
5.12.8. Respiratory Disorder
5.12.9. Others
5.13. Market Attractiveness Analysis
5.13.1. By Country
5.13.2. By Platform
5.13.3. By Product Type
5.13.4. By Application
5.13.5. By Therapeutic Area
5.14. Key Representative Market Participants
5.15. Market Presence (Intensity Map)
6. Western Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
6.3.1. Germany
6.3.2. Italy
6.3.3. France
6.3.4. Spain
6.3.5. U.K.
6.3.6. BENELUX
6.3.7. Nordic
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
6.4.1. Germany
6.4.2. Italy
6.4.3. France
6.4.4. Spain
6.4.5. U.K.
6.4.6. BENELUX
6.4.7. Nordic
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
6.5.1. Mammalian-based
6.5.2. Microbial-based
6.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
6.6.1. Mammalian-based
6.6.2. Microbial-based
6.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
6.7.1. Monoclonal Antibodies
6.7.2. Recombinant Proteins
6.7.3. Vaccines
6.7.4. Insulin
6.7.5. Interferons
6.7.6. Growth Factors
6.7.7. Others
6.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
6.8.1. Monoclonal Antibodies
6.8.2. Recombinant Proteins
6.8.3. Vaccines
6.8.4. Insulin
6.8.5. Interferons
6.8.6. Growth Factors
6.8.7. Others
6.9. Historical Market Size (US$ Mn) By Application, 2012-2016
6.9.1. Clinical
6.9.2. Commercial
6.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
6.10.1. Clinical
6.10.2. Commercial
6.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
6.11.1. Autoimmune Disease
6.11.2. Oncology
6.11.3. Metabolic Disease
6.11.4. Opthalmology
6.11.5. Cardiovascular Disease
6.11.6. Infectious Disease
6.11.7. Neurology
6.11.8. Respiratory Disorder
6.11.9. Others
6.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
6.12.1. Autoimmune Disease
6.12.2. Oncology
6.12.3. Metabolic Disease
6.12.4. Opthalmology
6.12.5. Cardiovascular Disease
6.12.6. Infectious Disease
6.12.7. Neurology
6.12.8. Respiratory Disorder
6.12.9. Others
6.13. Market Attractiveness Analysis
6.13.1. By Country
6.13.2. By Platform
6.13.3. By Product Type
6.13.4. By Application
6.13.5. By Therapeutic Area
6.14. Key Representative Market Participants
6.15. Market Presence (Intensity Map)
7. Eastern Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Trends
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.4.1. Russia
7.4.2. Poland
7.4.3. Rest of Eastern Europe
7.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
7.5.1. Mammalian-based
7.5.2. Microbial-based
7.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
7.6.1. Mammalian-based
7.6.2. Microbial-based
7.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
7.7.1. Monoclonal Antibodies
7.7.2. Recombinant Proteins
7.7.3. Vaccines
7.7.4. Insulin
7.7.5. Interferons
7.7.6. Growth Factors
7.7.7. Others
7.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
7.8.1. Monoclonal Antibodies
7.8.2. Recombinant Proteins
7.8.3. Vaccines
7.8.4. Insulin
7.8.5. Interferons
7.8.6. Growth Factors
7.8.7. Others
7.9. Historical Market Size (US$ Mn) By Application, 2012-2016
7.9.1. Clinical
7.9.2. Commercial
7.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
7.10.1. Clinical
7.10.2. Commercial
7.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
7.11.1. Autoimmune Disease
7.11.2. Oncology
7.11.3. Metabolic Disease
7.11.4. Opthalmology
7.11.5. Cardiovascular Disease
7.11.6. Infectious Disease
7.11.7. Neurology
7.11.8. Respiratory Disorder
7.11.9. Others
7.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
7.12.1. Autoimmune Disease
7.12.2. Oncology
7.12.3. Metabolic Disease
7.12.4. Opthalmology
7.12.5. Cardiovascular Disease
7.12.6. Infectious Disease
7.12.7. Neurology
7.12.8. Respiratory Disorder
7.12.9. Others
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Platform
7.13.3. By Product Type
7.13.4. By Application
7.13.5. By Therapeutic Area
7.14. Key Representative Market Participants
7.15. Market Presence (Intensity Map)
8. Asia Pacific excluding Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. South Korea
8.3.6. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. South Korea
8.4.6. Rest of APEJ
8.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
8.5.1. Mammalian-based
8.5.2. Microbial-based
8.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
8.6.1. Mammalian-based
8.6.2. Microbial-based
8.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
8.7.1. Monoclonal Antibodies
8.7.2. Recombinant Proteins
8.7.3. Vaccines
8.7.4. Insulin
8.7.5. Interferons
8.7.6. Growth Factors
8.7.7. Others
8.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
8.8.1. Monoclonal Antibodies
8.8.2. Recombinant Proteins
8.8.3. Vaccines
8.8.4. Insulin
8.8.5. Interferons
8.8.6. Growth Factors
8.8.7. Others
8.9. Historical Market Size (US$ Mn) By Application, 2012-2016
8.9.1. Clinical
8.9.2. Commercial
8.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
8.10.1. Clinical
8.10.2. Commercial
8.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
8.11.1. Autoimmune Disease
8.11.2. Oncology
8.11.3. Metabolic Disease
8.11.4. Opthalmology
8.11.5. Cardiovascular Disease
8.11.6. Infectious Disease
8.11.7. Neurology
8.11.8. Respiratory Disorder
8.11.9. Others
8.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
8.12.1. Autoimmune Disease
8.12.2. Oncology
8.12.3. Metabolic Disease
8.12.4. Opthalmology
8.12.5. Cardiovascular Disease
8.12.6. Infectious Disease
8.12.7. Neurology
8.12.8. Respiratory Disorder
8.12.9. Others
8.13. Market Attractiveness Analysis
8.13.1. By Country
8.13.2. By Platform
8.13.3. By Product Type
8.13.4. By Application
8.13.5. By Therapeutic Area
8.14. Key Representative Market Participants
8.15. Market Presence (Intensity Map)
9. Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Dynamics
9.2.1. Drivers
9.2.2. Restraints
9.2.3. Trends
9.3. Historical Market Size (US$ Mn) By Platform, 2012-2016
9.3.1. Mammalian-based
9.3.2. Microbial-based
9.4. Market Size (US$ Mn) Forecast By Platform, 2017-2027
9.4.1. Mammalian-based
9.4.2. Microbial-based
9.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
9.5.1. Monoclonal Antibodies
9.5.2. Recombinant Proteins
9.5.3. Vaccines
9.5.4. Insulin
9.5.5. Interferons
9.5.6. Growth Factors
9.5.7. Others
9.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
9.6.1. Monoclonal Antibodies
9.6.2. Recombinant Proteins
9.6.3. Vaccines
9.6.4. Insulin
9.6.5. Interferons
9.6.6. Growth Factors
9.6.7. Others
9.7. Historical Market Size (US$ Mn) By Application, 2012-2016
9.7.1. Clinical
9.7.2. Commercial
9.8. Market Size (US$ Mn) Forecast By Application, 2017-2027
9.8.1. Clinical
9.8.2. Commercial
9.9. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
9.9.1. Autoimmune Disease
9.9.2. Oncology
9.9.3. Metabolic Disease
9.9.4. Opthalmology
9.9.5. Cardiovascular Disease
9.9.6. Infectious Disease
9.9.7. Neurology
9.9.8. Respiratory Disorder
9.9.9. Others
9.10. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
9.10.1. Autoimmune Disease
9.10.2. Oncology
9.10.3. Metabolic Disease
9.10.4. Opthalmology
9.10.5. Cardiovascular Disease
9.10.6. Infectious Disease
9.10.7. Neurology
9.10.8. Respiratory Disorder
9.10.9. Others
9.11. Market Attractiveness Analysis
9.11.1. By Platform
9.11.2. By Product Type
9.11.3. By Application
9.11.4. By Therapeutic Area
9.12. Key Representative Market Participants
9.13. Market Presence (Intensity Map)
10. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
10.3.1. GCC Countries
10.3.2. Turkey
10.3.3. North Africa
10.3.4. South Africa
10.3.5. Rest of MEA
10.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
10.4.1. GCC Countries
10.4.2. Turkey
10.4.3. North Africa
10.4.4. South Africa
10.4.5. Rest of MEA
10.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
10.5.1. Mammalian-based
10.5.2. Microbial-based
10.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
10.6.1. Mammalian-based
10.6.2. Microbial-based
10.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
10.7.1. Monoclonal Antibodies
10.7.2. Recombinant Proteins
10.7.3. Vaccines
10.7.4. Insulin
10.7.5. Interferons
10.7.6. Growth Factors
10.7.7. Others
10.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
10.8.1. Monoclonal Antibodies
10.8.2. Recombinant Proteins
10.8.3. Vaccines
10.8.4. Insulin
10.8.5. Interferons
10.8.6. Growth Factors
10.8.7. Others
10.9. Historical Market Size (US$ Mn) By Application, 2012-2016
10.9.1. Clinical
10.9.2. Commercial
10.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
10.10.1. Clinical
10.10.2. Commercial
10.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
10.11.1. Autoimmune Disease
10.11.2. Oncology
10.11.3. Metabolic Disease
10.11.4. Opthalmology
10.11.5. Cardiovascular Disease
10.11.6. Infectious Disease
10.11.7. Neurology
10.11.8. Respiratory Disorder
10.11.9. Others
10.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
10.12.1. Autoimmune Disease
10.12.2. Oncology
10.12.3. Metabolic Disease
10.12.4. Opthalmology
10.12.5. Cardiovascular Disease
10.12.6. Infectious Disease
10.12.7. Neurology
10.12.8. Respiratory Disorder
10.12.9. Others
10.13. Market Attractiveness Analysis
10.13.1. By Country
10.13.2. By Platform
10.13.3. By Product Type
10.13.4. By Application
10.13.5. By Therapeutic Area
10.14. Key Representative Market Participants
10.15. Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Competition Dashboard
13.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
13.2.1. Lonza Group AG
13.2.2. Baxter Biopharma Solutions
13.2.3. Samsung Biologics Co., Ltd.
13.2.4. Fujifilm Diosynth Biotechnologies
13.2.5. Boehringer Ingelheim GmbH
13.2.6. Patheon N.V.
13.2.7. Rentschler Biotechnologie GmbH
13.2.8. Biomeva GmbH
13.2.9. Probiogen AG
13.2.10. Cytovance Biologics, Inc.
13.2.11. KBI Biopharma, Inc.
13.2.12. WuXi Biologics
13.2.13. Abzena Plc
13.2.14. Vetter Pharma International GmbH
13.2.15. Sandoz International GmbH
13.2.16. Catalent, Inc.
13.2.17. AbbVie Contract Manufacturing (An AbbVie Company)
13.2.18. Ajinomoto Althea, Inc.
14. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2016
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific excluding Japan
14.2.6. Japan
14.2.7. Middle East & Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2017–2027
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific excluding Japan
14.3.6. Japan
14.3.7. Middle East & Africa
14.4. Market Attractiveness Analysis By Region
15. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Platform
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Platform, 2012–2016
15.2.1. Mammalian-based
15.2.2. Microbial-based
15.3. Market Size (US$ Mn) Forecast By Platform, 2017–2027
15.3.1. Mammalian-based
15.3.2. Microbial-based
15.4. Market Attractiveness Analysis By Platform
16. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Product Type
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2012–2016
16.2.1. Monoclonal Antibodies
16.2.2. Recombinant Proteins
16.2.3. Vaccines
16.2.4. Insulin
16.2.5. Interferons
16.2.6. Growth Factors
16.2.7. Others
16.3. Market Size (US$ Mn) Forecast By Product Type, 2017–2027
16.3.1. Monoclonal Antibodies
16.3.2. Recombinant Proteins
16.3.3. Vaccines
16.3.4. Insulin
16.3.5. Interferons
16.3.6. Growth Factors
16.3.7. Others
16.4. Market Attractiveness Analysis By Product Type
17. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Application
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Analysis By Application, 2012–2016
17.2.1. Clinical
17.2.2. Commercial
17.3. Market Size (US$ Mn) Forecast By Application, 2017–2027
17.3.1. Clinical
17.3.2. Commercial
17.4. Market Attractiveness Analysis By Application
18. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2012–2016
18.2.1. Autoimmune Disease
18.2.2. Oncology
18.2.3. Metabolic Disease
18.2.4. Opthalmology
18.2.5. Cardiovascular Disease
18.2.6. Infectious Disease
18.2.7. Neurology
18.2.8. Respiratory Disorder
18.2.9. Others
18.3. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
18.3.1. Autoimmune Disease
18.3.2. Oncology
18.3.3. Metabolic Disease
18.3.4. Opthalmology
18.3.5. Cardiovascular Disease
18.3.6. Infectious Disease
18.3.7. Neurology
18.3.8. Respiratory Disorder
18.3.9. Others
18.4. Market Attractiveness Analysis By Therapeutic Area
19. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
19.3. Market Value Chain
List of Tables
Table 01: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 02: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 03: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 04: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 05: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 06: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 07: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 08: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 09: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 10: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 11: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 12: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 13: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 14: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 15: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 16: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 17: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 18: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 19: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 20: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 21: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 22: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 23: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 24: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 25: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 26: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 27: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 28: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 29: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 30: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 31: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 32: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 33: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 34: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
Table 35: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Region
Table 36: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform
Table 37: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type
Table 38: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 39: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report